Related Experiment Video
Updated: Sep 26, 2025
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Serum Metabolites Associated with Blood Pressure in Chronic Kidney Disease Patients
Fengyao Yan1, Dan-Qian Chen2, Jijun Tang1
1Department of Computer Science, University of South Carolina, Columbia, SC 37027, USA.
Insights
High blood pressure in chronic kidney disease (CKD) patients is linked to ten key metabolites. Seven of these, including aspartylglycosamine, show novel associations, suggesting potential metabolite supplements for blood pressure control.
Area of Science:
- Nephrology
- Metabolomics
- Cardiovascular Health
Background:
- Blood pressure management is critical for patients with chronic kidney disease (CKD).
- Hypertension in CKD accelerates kidney function decline and increases cardiovascular disease risk.
- Understanding the metabolic underpinnings of blood pressure in CKD is essential.
Purpose of the Study:
- To identify novel serum metabolites associated with blood pressure in CKD patients.
- To validate the quantitative importance of identified metabolites using a machine learning model.
- To explore potential therapeutic targets for blood pressure control in CKD.
Main Methods:
- Recruitment of two independent CKD cohorts with matched controls (total n = 1376).
- High-throughput serum metabolomics analysis using mass spectrometry.
- Statistical analysis to identify metabolite associations with blood pressure, controlling for clinical factors.
- Validation using a fully connected neural network model.
Main Results:
- Ten serum metabolites showed significant associations with blood pressure in CKD patients after adjustment.
- Seven of these metabolites have not been previously linked to blood pressure.
- Aspartylglycosamine, fructose-1,6-diphosphate, and N-Acetylserine showed the strongest positive associations.
- Phosphocreatine, dodecanedioic acid, and phosphate were negatively associated with blood pressure.
Conclusions:
- Novel serum metabolites are significantly associated with blood pressure in CKD.
- Metabolite profiles may offer new insights into hypertension mechanisms in CKD.
- Targeting specific metabolites through supplementation could be a future strategy for blood pressure management in CKD patients.
Abstract:
Blood pressure is one of the most basic health screenings and it has a complex relationship with chronic kidney disease (CKD). Controlling blood pressure for CKD patients is crucial for curbing kidney function decline and reducing the risk of cardiovascular disease. Two independent CKD cohorts, including matched controls (discovery n = 824; validation n = 552), were recruited. High-throughput metabolomics was conducted with the patients' serum samples using mass spectrometry. After controlling for CKD severity and other clinical hypertension risk factors, we identified ten metabolites that have significant associations with blood pressure. The quantitative importance of these metabolites was verified in a fully connected neural network model. Of the ten metabolites, seven have not previously been associated with blood pressure. The metabolites that had the strongest positive association with blood pressure were aspartylglycosamine (p = 4.58 × 10-5), fructose-1,6-diphosphate (p = 1.19 × 10-4) and N-Acetylserine (p = 3.27 × 10-4). Three metabolites that were negatively associated with blood pressure (phosphocreatine, p = 6.39 × 10-3; dodecanedioic acid, p = 0.01; phosphate, p = 0.04) have been reported previously to have beneficial effects on hypertension. These results suggest that intake of metabolites as supplements may help to control blood pressure in CKD patients.
Related Concept Videos
01:24Serum Studies: Renal Function Tests
01:28Chronic Kidney Disease III: Interprofessional Care
01:24Chronic Kidney Disease II: Clinical Manifestations
01:25Chronic Kidney Disease I: Introduction
01:18Chronic Kidney Disease IV: Nursing Management
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies